Teva Launches Generic Xeloda Tablets

Share this content:
Teva Launches Generic Xeloda Tablets
Teva Launches Generic Xeloda Tablets

Teva Pharmaceuticals announced the launch of Capecitabine Tablets, the generic equivalent to Genentech's Xeloda. Teva is the first company to receive approval for its ANDA for Capecitabine Tablets.

Xeloda is a fluoropyrimidine indicated for metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel when further anthracycline therapy is not indicated; and with docetaxel for metastatic breast cancer after failure of prior anthracycline-containing regimen.

RELATED: Breast Cancer Resource Center

Capecitabine is available in 150mg and 500mg strength tablets.

For more information call (888) 838-2872 or visit

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs